

Mumbai, May 27, 2013

Wockhardt Crosses the billion dollar mark

\$1Bn in Sales

**Continues to be amongst the Top Pharma Companies
on PAT & Operating Profit Growth**

with

365% Growth in Profit After Tax at Rs.1594 crores

52% Growth in Operating Profit at Rs.2091 crores

29% Growth in Revenues at Rs.5610 crores

in 2012-13



PRESS RELEASE



	Q4-FY13		Q4-FY12	FY13		FY12
	Jan - Mar 2013		Jan - Mar 2012	Apr - Mar 2013		Apr - Mar 2012
	Rsc	Gwth Y-O-Y	Rsc	Rsc	Gwth Y-O-Y	Rsc
Sales	1,486	26%	1,175	5,610	29%	4,351
Operating Profit	546	32%	414	2,091	52%	1,377
Op. Profit Margins %	36.7%		35.2%	37.3%		31.6%
Profit After Tax	335		(192)	1,594	365%	343
PAT Margins	22.5%		-16.3%	28.4%		7.9%
EPS	30.6		(17.5)	145.6	365%	31.3

Financial Year 2012-13

Wockhardt Limited, the Pharmaceutical and Biotechnology major reported once again a good performance with consolidated revenue of Rs. 5610 Crores, and a Profit After Tax of Rs.1594 crores in the Financial Year 2012-13. The Profit After Tax margin is at 28.4%.

Consolidated revenues showed a growth of 29% and the Profit After Tax grew by 365% over Financial Year 2011-12 respectively.

Wockhardt's Operating Profit for Financial Year 2012-13 stands at Rs.2091 crores, with Operating Profit Margin at 37.3%, one of the highest in the industry and has improved from 31.6% in Financial Year 2011-12.

According to Dr. Habil Khorakiwala, Founder Chairman and Group CEO, Wockhardt Ltd, *"the strong growth that we have achieved in this financial year is the result of a robust global strategy, continued focus on R&D and the commitment and confidence of Team Wockhardt. Driving profitable growth is integral to our business strategy."*

PRESS RELEASE

WOCKHARDT

Quarter ended 31st Mar 2013

The Profit After Tax for Q4FY13 stood at Rs.335 crores compared to a loss of Rs.192 crores reported in corresponding quarter in the previous year.

The Operating Profit was at Rs.546 crores for Q4FY13, representing a growth of 32% over corresponding quarter in the previous year. Operating Profit margins were at 36.7% for Q4FY13.

Consolidated revenues grew by 26% to Rs. 1486 crores over the corresponding quarter in the previous year.

Other Financials

The Earnings Per Share was at Rs. 145.6 for the Financial Year 2012-13.

Research & Development

R&D continues to be at the core for Wockhardt. During the year 2012-13 R&D expenses stood at 6.7% of sales compared to 5.7% of sales in 2011-12.

Wockhardt filed 20 new product applications with USFDA in Financial Year 2012-13 and received approvals for 12 products during the year. Cumulative products pending approval with USFDA stands at 46 as on March 2013.

Wockhardt also filed for 162 patents during the year taking the cumulative filings to 1733 and has been granted 52 patents during the year taking the cumulative patents granted to 206. Wockhardt won the Pharmexcil Award for the highest number of patents filed for the 4th year in a row.

Dr. Habil Khorakiwala, Founder Chairman and Group CEO, Wockhardt Ltd., further added, "R&D continues to be at the core of the organisation. We have undertaken significant investments in talent and new technologies at R&D to keep it at the forefront of latest developments. With R&D at 6.7% of sales, the organisation maintains one of the best investments in the industry towards its R&D programs."

Dividend

The board of directors have recommended a dividend of 100% on equity shares i.e. Rs.5/- per share.

Business Highlights

Wockhardt's International Business contributed 83% of the Total Revenues during the quarter.

Wockhardt's US business recorded a growth of 52% in Financial Year 2012-13 compared to the Financial Year 2011-12. The growth in the US market was mainly driven by cache of niche launches including its 2 FTF products during the year.

The growth was also aided by increase in market share of some key products. Wockhardt now has 18 products which are at no. 1 position and 17 products which are at no. 2 position in the US market.

The UK business recorded a growth of 24% in Financial Year 2012-13 in an otherwise stagnant market. The Irish market recorded a growth of 13% in Financial Year 2012-13.

The India business grew by 8% and the Emerging Markets business grew by 24% in Financial Year 2012-13.

Wockhardt Limited has organized a conference call and webcast for investors and analysts on Tuesday, May 28, 2013 from 11am - 12noon IST. The details of the webcast and conference call are as follows:

Timing	:	11:00 am IST on Tuesday, May 28, 2013
¹Webcast link	:	http://cs3-ipresent.choruscall.com/FlexPresenter
¹Webcast user-name	:	<your name>
¹Webcast passcode	:	6665411
²Conference dial-in Primary number	:	+91 22 6629 0301 / +91 22 3065 0122
Hong Kong Local Access Number	:	800 964 448
Singapore Local Access Number	:	800 101 2045
UK Local Access Number	:	0 808 101 1573
USA Local Access Number	:	1 866 746 2133
Replay Facility	:	Available until June 2, 2013 on + 91 22 3065 1212 Play Back ID – 12741# Replay will be available 2 hours after the call ends

¹For viewing the presentation while it is being discussed by the management

²For audio and the question and answer session

About Wockhardt :

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with more than 80% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 206 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7900 people from 21 different nationalities.